Skip to main content
. 2015 Mar 5;106(3):262–269. doi: 10.1111/cas.12603

Figure 3.

Figure 3

CXCR2 and CXCL7 transcript levels and CXCR2 immunostaining in liver metastases from patients who received neoadjuvant chemotherapy (NC) associated with, or not associated with, bevacizumab (beva). (a, b) Comparison of CXCR2 and CXCL7 transcript levels from patients treated by neoadjuvant chemotherapy with or without bevacizumab prior to hepatic surgery. (c, d) Histologic examination with hematoxylin, eosin, saffron and Astra blue and CXCR2 immunostaining of liver metastases from two patients treated by neoadjuvant chemotherapy with (c) or without (d) bevacizumab (c,d magnification, ×100 and ×400, respectively).